What does NCFBR stand for?

INTRODUCTION While debate continues regarding the lack of an evidence base for airway clearance techniques (ACTs) in Cystic Fibrosis (CF) and non-CF bronchiectasis (BX) management (Jones and Rowe 2007, Wallis and Prasad 1999), clinical guidelines continue to recommend these as best practice (Chang et al 2002, Edwards et al 2004b, Cystic Fibrosis Trust 2002, Lannefors et al 2004).

This treatment resulted in high concentrations of ciprofloxacin in the sputum leading to a significant reduction in the number of colony forming units (CFU) of Pseudomonas Aeruginosa in the sputum, an objective measure of the reduction in pulmonary bacterial load in the CF and non-CF bronchiectasis patients.

Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data from its Phase 2a studies of inhaled liposomal ciprofloxacin in cystic fibrosis (CF) and in non-CF bronchiectasis (BE) patients at the 2009 International Conference of the American Thoracic Society in San Diego, California.